Marco Rubatto
University of Turin
45 Papers
43 Citations
Marco Rubatto is an academic researcher from University of Turin. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 4, co-authored 16 publications.
Chat about Author
Papers
Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma.
Alice Baggi,Pietro Quaglino,Marco Rubatto,Roberta Depenni,Michele Guida,Paolo A. Ascierto,Claudia Trojaniello,Paola Queirolo,Maristella Saponara,K. Peris,Francesco Spagnolo,Luca Bianchi,Federica De Galitiis,Maria Concetta Potenza,Ilaria Proietti,Riccardo Marconcini,Andrea Botticelli,Vito Barbieri,Lisa Licitra,Salvatore Alfieri,Corrado Ficorella,Alessio Cortellini,Maria Concetta Fargnoli,Teresa Troiani,Luca Tondulli,Paolo Bossi +25 more
TL;DR: In this paper, the authors report clinical outcomes from the named patient programme-compassionate use of cemiplimab for patients with advanced cutaneous squamous cell carcinoma in Italy.
84
The Effect of the COVID-19 Lockdown on Melanoma Diagnosis in Italy
Giulio Gualdi,Annamaria Porreca,Giuseppe Amoruso,Laura Atzori,Piergiacomo Calzavara-Pinton,Michele De Tursi,Andrea Di Buduo,Pietro Di Marino,Gabriella Fabroncini,Fabrizio Fantini,Maria Concetta Fargnoli,Gaetano Giannotta,Francesco Lacarruba,Andrea Lotesoriere,Martina Merli,Giuseppe Micali,Andrea Paradisi,Mario Puviani,Pietro Quaglino,Franco Rongioletti,Marco Rubatto,Paolo Sbano,Massimiliano Scalvenzi,Simone Soglia,Laura Sollima,Alessia Villani,Marta Di Nicola,Paolo Amerio +27 more
TL;DR: In this paper, a retrospective observational cohort study was conducted to estimate the impact on melanoma progression caused by the reduction in dermatologic services during the COVID-19 lockdown in Italy.
43
Patients with psoriasis resistant to multiple biological therapies: characteristics and definition of a difficult‐to‐treat population
Luca Mastorino,G. Roccuzzo,Paolo Dapavo,Niccolò Siliquini,Gianluca Avallone,Marco Rubatto,Martina Merli,Andrea Agostini,Simone Ribero,Pietro Quaglino +9 more
TL;DR: It is the opinion that patients without response to at least four biologics should fall into the category of multi-failure (or multi-resistant) patients, and among 783 patients treated between November 2020 and November 2021 the authors identified 10 multi- resistant patients.
21
Metastatic melanoma treatment with checkpoint inhibitors in the COVID-19 era: experience from an Italian Skin Cancer Unit.
Pietro Quaglino,Paolo Fava,Matteo Brizio,Elena Marra,Marco Rubatto,Andrea Agostini,Luca Tonella,Simone Ribero,Maria Teresa Fierro +8 more
TL;DR: The most important risk factors related to a higher death risk for COVID-19 pneumonia are elderly age and comorbidities (hypertension, diabetes, previous cancer).
18
Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer
Marco Rubatto,Nadia Sciamarrelli,Silvia Borriello,Valentina Pala,Luca Mastorino,Luca Tonella,Simone Ribero,Pietro Quaglino +7 more
TL;DR: The combination therapy of nivolumab plus ipilimumab has gained ground in studies for its survival and response rate benefits in patients with advanced melanoma and non-melanoma skin cancers as mentioned in this paper .
15